New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer’s disease

STOCKHOLM, July 13, 2026 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous…

Source: prnewswire

Country: United States